Cosmos Health Inc. has reported that its proprietary antiseptic brands, C-Scrub and C-Sept, have generated over $1.5 million in combined annualized sales across the United Kingdom and Greece. The company is targeting a significant expansion into additional European Union markets, with goals to reach $7.4 million in revenue and $5.3 million in gross profit within three years.

The brands currently achieve gross margins above 70%, making them a high-margin pillar within Cosmos Health's portfolio. Nearly half of the sales originate from the United Kingdom, where C-Scrub holds close to 900 ratings on Amazon, predominantly 5-star, and is available via Tesco and Superdrug. In Greece, momentum is driven through the hospital channel, reflecting adoption among healthcare professionals.

Cosmos Health has outlined a three-year growth trajectory for C-Scrub and C-Sept, supported by continued expansion in existing markets and entry into new EU countries. The company projects that gross margins will remain consistent at approximately 72%.

Three-Year Financial Targets

Strategic Expansion Initiatives

To achieve these targets, Cosmos Health is pursuing entry into hospital and clinical settings, leveraging the suitability of its antiseptic products for professional hygiene. Additionally, the company is extending C-Scrub into the animal healthcare market, broadening its addressable market to include veterinary use. Management believes these initiatives may lead to an upward revision of the current targets.

Greg Siokas, CEO of Cosmos Health, stated that the company is building a high-margin antiseptics business with significant competitive advantages. He highlighted that the brands are fast becoming a flagship growth engine and a meaningful contributor to revenue, cash flow, and long-term shareholder value as the company expands across the EU and into animal healthcare.

Cosmos Health Inc. has entered into a non-binding letter of intent to acquire 100% of Doc Pharma S.A., a fully licensed GMP pharmaceutical manufacturer, in a move designed to deepen vertical integration and expand production capacity. The proposed acquisition is expected to be immediately accretive, supporting margin expansion, profitability, and cash flow for the global healthcare group. Doc Pharma operates a state-of-the-art, GMP-licensed production plant spanning approximately 59,000 square feet, built to the highest European standards.

Strategic and Financial Rationale

The transaction constitutes a related-party transaction and will be reviewed by a committee of independent directors, supported by an independent fairness opinion and valuation, as well as a PCAOB audit. Completion is subject to shareholder approval and final due diligence. Cosmos Health expects the deal to capture value across the entire value chain through economies of scale and optimized production.

Doc Pharma Financial Profile

Doc Pharma brings a significant asset base and established revenue stream to Cosmos Health. The financial figures represent average annual figures for the three most recent completed financial years, FY2023, FY2024, and FY2025, converted from euros into U.S. dollars based on the applicable EUR/USD exchange rate as of June 11, 2026.

Operational Capabilities

The acquisition will broaden the dosage forms Cosmos Health can manufacture in-house, including tablets, hard capsules, sachets, syrups, suspensions, solutions, drops, and sprays. Doc Pharma holds comprehensive certifications, including GMP, ISO, Kosher, and Halal, with site registrations for the UAE, Qatar, Iraq, and Lebanon. The facility features independent chemical and microbiological laboratories operating to GLP guidelines, with testing aligned to European, British, and US Pharmacopeia monographs.

Management Commentary

Greg Siokas, CEO of Cosmos Health, stated that the acquisition is a defining step in the company's vision to build a global, diversified, vertically integrated healthcare powerhouse. He highlighted that bringing Doc Pharma's state-of-the-art GMP facility and deep portfolio of advanced and branded generics in-house is expected to expand production capacity, accelerate growth, and strengthen margins.